Catalog No.: PC-62121Not For Human Use, Lab Use Only.
Theliatinib (HMPL309) is a highly selective, potent, ATP-competitive inhibitor of EGFR with IC50 of 3 nM/22 nM for EGFR/EGFRT790M/L858R mutant, respectively.
Theliatinib (HMPL309) is a highly selective, potent, ATP-competitive inhibitor of EGFR with IC50 of 3 nM/22 nM for EGFR/EGFRT790M/L858R mutant, respectively.
Theliatinib (HMPL309) demonstrates 50-fold greater selectivity for EGFR compared to 72 other kinases.
Theliatinib (HMPL309) inhibits EGFR phosphorylation (IC50=7 nM) and cell survival in tumor cells
Theliatinib (HMPL309) shows in vivo activity in multiple xerographs such as A-431, Bcap-37 and Fadu; generally well tolerated in animals and orally bioactive.
